结核分枝杆菌利福平耐药分子检测结果不一致的频率、机制与临床影响
该研究在南非三省749例利福平耐药结核病患者中比较分子检测结果的一致性,发现Xpert MTB/RIF与MTBDRplus不一致率为14.5%,连续两次Xpert为5.6%,连续两次MTBDRplus为4.2%。不一致原因包括MTBDRplus假敏感、分子检测假耐药及人为错误,33%的不一致患者治疗方案被调整,追加Xpert检测可在至少73%的不一致病例中获得真实利福平耐药诊断。
要点
- Xpert与MTBDRplus利福平耐药结果不一致率高达14.5%。
- 不一致机制包括探针未覆盖变异、异质性耐药丢失及人为错误。
- 追加Xpert检测可在至少73%不一致病例中明确真实耐药状态。
核心结论
- Xpert与MTBDRplus之间利福平耐药结果不一致率较高,对实验室、临床医生和患者均有重要影响。
- 尽管不一致原因多样,追加Xpert检测可在多数患者中指导正确治疗。
研究设计与样本
- 在南非三个省749例利福平耐药结核病患者中成对比较分子检测结果以确定不一致率。
- 培养分离株送至研究实验室进行全基因组测序和利福平MIC测定,并通过病历回顾收集临床信息。
主要发现
- Xpert MTB/RIF与MTBDRplus不一致率为14.5%(95% CI 10.9%-18.9%)。
- 连续两次Xpert不一致率为5.6%(95% CI 2.2%-13.4%),连续两次MTBDRplus不一致率为4.2%(95% CI 2.2%-7.8%)。
- 可能机制包括MTBDRplus假敏感(突变探针未覆盖的变异或培养中丢失次要变异体的异质性耐药)、利福平敏感分离株分子检测假耐药及人为错误。
- 33%的不一致患者治疗方案被医务人员调整,460例完成首次确认检测后追加了232次分子检测。
- 追加Xpert检测可在至少73%的不一致病例中为医务人员提供真实的利福平耐药结核诊断。
临床怎么用
- 当Xpert与MTBDRplus利福平耐药结果不一致时,可追加Xpert检测以辅助确定真实耐药状态并指导治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Molecular assays are endorsed for detection and confirmation of rifampicin-resistant TB. The frequency, causal mechanisms and impact of discordant results between molecular tests are not well understood. METHODS: The prevalence of discordant results was determined by pairwise comparison of molecular test results in a cohort of 749 rifampicin-resistant TB patients in three South African provinces. Culture isolates were sent to a research laboratory for WGS and rifampicin MIC determination. Clinical information was collected through medical file review. RESULTS: The prevalence of discordances between Xpert MTB/RIF and MTBDRplus was 14.5% (95% CI 10.9%-18.9%), 5.6% (95% CI 2.2%-13.4%) between two consecutive Xpert assays and 4.2% (95% CI 2.2%-7.8%) between two consecutive MTBDRplus assays. Likely mechanisms of discordances were false rifampicin susceptibility on MTBDRplus (due to variants not included in mutant probes or heteroresistance with loss of minor variants in culture), false resistance on molecular assay in rifampicin-susceptible isolates, and human error. The healthcare worker changed the treatment regimen in 33% of patients with discordant results and requested 232 additional molecular tests after a first confirmatory test was performed in 460 patients. A follow-up Xpert assay would give the healthcare worker the 'true' rifampicin-resistant TB diagnosis in at least 73% of discordant cases. CONCLUSIONS: The high rate of discordant results between Xpert and MTBDRplus has important implications for the laboratory, clinician and patient. While root causes for discordant result are multiple, a follow-up Xpert assay could guide healthcare workers to the correct treatment in most patients.
引用
- Van Rie A, Whitfield MG, De Vos E, et al. Discordances between molecular assays for rifampicin resistance in Mycobacterium tuberculosis: frequency, mechanisms and clinical impact. J Antimicrob Chemother. 2020. PMID: 32016320. doi:10.1093/jac/dkz564
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。